IL-17 signalling is known to activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-Activated Protein Kinase (MAPK) pathways, which are involved in tumour progression, aberrant proliferation, and metastasis, contributing to poor clinical outcomes. This evidence concerns the gene IL17A and neoplasm.